MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Oct 14

PMID 37835417

Authors

Junjiang Fu

Saber Imani

Mei-Yi Wu

Ray-Chang Wu

Affiliations

Soon will be listed here.

Abstract

MicroRNA (miRNA) are small noncoding RNAs that play vital roles in post-transcriptional gene regulation by inhibiting mRNA translation or promoting mRNA degradation. The dysregulation of miRNA has been implicated in numerous human diseases, including cancers. miR-34 family members (miR-34s), including miR-34a, miR-34b, and miR-34c, have emerged as the most extensively studied tumor-suppressive miRNAs. In this comprehensive review, we aim to provide an overview of the major signaling pathways and gene networks regulated by miR-34s in various cancers and highlight the critical tumor suppressor role of miR-34s. Furthermore, we will discuss the potential of using miR-34 mimics as a novel therapeutic approach against cancer, while also addressing the challenges associated with their development and delivery. It is anticipated that gaining a deeper understanding of the functions and mechanisms of miR-34s in cancer will greatly contribute to the development of effective miR-34-based cancer therapeutics.

Citing Articles

Macrophage-derived lncRNAs in cancer: regulators of tumor progression and therapeutic targets.

Suliman M, Saleh R, Chandra M, Rasool K, Jabir M, Jawad S Med Oncol. 2025; 42(4):91.

PMID: 40048034 DOI: 10.1007/s12032-025-02643-2.

Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.

Lv J, Song X, Luo Z, Huang D, Xiao L, Zou K Front Pharmacol. 2025; 16:1535555.

PMID: 40012626 PMC: 11861102. DOI: 10.3389/fphar.2025.1535555.

miRNA Signatures as Predictors of Therapy Response in Castration-Resistant Prostate Cancer: Insights from Clinical Liquid Biopsies and 3D Culture Models.

Puente-Rivera J, Nunez-Olvera S, Fernandez-Sanchez V, Cureno-Diaz M, Gomez-Zamora E, Plascencia-Nieto E Genes (Basel). 2025; 16(2).

PMID: 40004509 PMC: 11855684. DOI: 10.3390/genes16020180.

Retinopathy of Prematurity and MicroRNAs.

Albanese G, Visioli G, Alisi L, Armentano M, Giovannetti F, Lucchino L Biomedicines. 2025; 13(2).

PMID: 40002813 PMC: 11852721. DOI: 10.3390/biomedicines13020400.

Unveiling hotspots of emerging research in the miRNA-related mechanism underlying cancer through comprehensive bibliometric analysis with implications for precision medicine and non-invasive diagnostics.

Zhang Z, Song W, Chen W, Cui W, Chen W, Zhang Q Front Oncol. 2025; 14:1521251.

PMID: 39882450 PMC: 11774920. DOI: 10.3389/fonc.2024.1521251.

References

Bonetti P, Climent M, Panebianco F, Tordonato C, Santoro A, Marzi M . Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer. Oncogene. 2018; 38(3):360-374. PMC: 6336680. DOI: 10.1038/s41388-018-0445-3. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Soni K, Gupta S, Gokhale S, Dey R, Gunjal A, Kumar V . Detection and knockdown of microRNA-34a using thioacetamido nucleic acid. Nucleic Acid Ther. 2013; 23(3):195-202. DOI: 10.1089/nat.2012.0411. View

Pillai R, Bhattacharyya S, Filipowicz W . Repression of protein synthesis by miRNAs: how many mechanisms?. Trends Cell Biol. 2007; 17(3):118-26. DOI: 10.1016/j.tcb.2006.12.007. View

Samuel N, Wilson G, Said B, Pan A, Deblois G, Fischer N . Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network. Oncotarget. 2016; 7(31):49611-49622. PMC: 5226533. DOI: 10.18632/oncotarget.10417. View

Mizuno K, Mataki H, Arai T, Okato A, Kamikawaji K, Kumamoto T . The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes. J Hum Genet. 2017; 62(7):671-678. DOI: 10.1038/jhg.2017.27. View

Wang C, Xin H, Yan G, Liu Z . NONHSAG028908.3 sponges miR‑34a‑5p to promote growth of colorectal cancer via targeting ALDOA. Oncol Rep. 2023; 49(5). PMC: 10073408. DOI: 10.3892/or.2023.8526. View

Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H . The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-5. PMC: 3076220. DOI: 10.1038/nm.2284. View

Gupta J, K Abdulsahib W, Turki Jalil A, Kareem D, Aminov Z, Alsaikhan F . Prostate cancer and microRNAs: New insights into apoptosis. Pathol Res Pract. 2023; 245:154436. DOI: 10.1016/j.prp.2023.154436. View

10.

Huang Y, Wang L, Chen Y, Han H, Li Q . Lipoic Acid-Modified Oligoethyleneimine-Mediated miR-34a Delivery to Achieve the Anti-Tumor Efficacy. Molecules. 2021; 26(16). PMC: 8400101. DOI: 10.3390/molecules26164827. View

11.

Wu Y, Gao B, Qi X, Bai L, Li B, Bao H . Circular RNA ATAD1 is upregulated in acute myeloid leukemia and promotes cancer cell proliferation by downregulating miR-34b via promoter methylation. Oncol Lett. 2021; 22(5):799. PMC: 8477150. DOI: 10.3892/ol.2021.13060. View

12.

Imani S, Wu R, Fu J . MicroRNA-34 family in breast cancer: from research to therapeutic potential. J Cancer. 2018; 9(20):3765-3775. PMC: 6216011. DOI: 10.7150/jca.25576. View

13.

Xu K, Chen B, Li B, Li C, Zhang Y, Jiang N . DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer. Aging (Albany NY). 2020; 12(23):23668-23683. PMC: 7762500. DOI: 10.18632/aging.103820. View

14.

Chamani F, Sadeghizadeh M, Masoumi M, Babashah S . Evaluation of MiR-34 Family and DNA Methyltransferases 1, 3A, 3B Gene Expression Levels in Hepatocellular Carcinoma Following Treatment with Dendrosomal Nanocurcumin. Asian Pac J Cancer Prev. 2016; 17(S3):219-24. DOI: 10.7314/apjcp.2016.17.s3.219. View

15.

Liang X, Xu C, Wang W, Li X . The DNMT1/miR-34a Axis Is Involved in the Stemness of Human Osteosarcoma Cells and Derived Stem-Like Cells. Stem Cells Int. 2019; 2019:7028901. PMC: 6875320. DOI: 10.1155/2019/7028901. View

16.

Craig V, Cogliatti S, Imig J, Renner C, Neuenschwander S, Rehrauer H . Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011; 117(23):6227-36. PMC: 3790944. DOI: 10.1182/blood-2010-10-312231. View

17.

Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling K . MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 2015; 97:104-21. DOI: 10.1016/j.phrs.2015.04.015. View

18.

Craig V, Tzankov A, Flori M, Schmid C, Bader A, Muller A . Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 2012; 26(11):2421-4. DOI: 10.1038/leu.2012.110. View

19.

Slabakova E, Culig Z, Remsik J, Soucek K . Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017; 8(10):e3100. PMC: 5682661. DOI: 10.1038/cddis.2017.495. View

20.

Rose-Inman H, Kuehl D . Acute Leukemia. Hematol Oncol Clin North Am. 2017; 31(6):1011-1028. DOI: 10.1016/j.hoc.2017.08.006. View